Complement in monoclonal antibody therapy of cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Immunology
Link
http://link.springer.com/content/pdf/10.1007/s12026-014-8542-z.pdf
Reference67 articles.
1. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(8):2825–33.
2. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013;341(6151):1192–8. doi: 10.1126/science.1241145 .
3. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17(9):2639–48.
4. Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol. 2003;30(4):424–33.
5. Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011;11(9):777–92.
Cited by 93 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Plasma-based proteomic profiling identifies the distinct regulation of proteins in hyperplasia and endometrial cancer;BMC Cancer;2024-06-20
2. The double life of a chemotherapy drug: Immunomodulatory functions of gemcitabine in cancer;Cancer Medicine;2024-05
3. Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability;Drugs;2024-03
4. Development of Monoclonal Antibodies for the Treatment of Lymphoma;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21
5. New polyclonal antibodies, inhibit selectively tumor growth and invasion and synergize with immune checkpoint inhibitors;JCI Insight;2023-12-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3